El interés en corto de Arcellx da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Arcellx. Los datos de interés en corto se actualizan cada dos semanas.

Arcellx (NASDAQ:ACLX) Bolsa, Informe de interés en corto

Arcellx

Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.

Arcellx Inc

WIIM

IBM shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and announced a price target of $320.

On Monday, Germany-based Merck KGaA (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MKGAF#OTC">MKGAF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MKKGY#OTC">MKKGY</a>) reacted to press reports and confirmed advanced discussions with SpringWorks Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>), which has a market capitalization of $4.02 billion, according to data from <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.
Merck Germany also <a target="_blank" href="https://www.emdgroup.com/ad-hoc/us/ad-hoc-NA-10Feb2025.pdf" rel="noreferrer noopener">confirmed</a> that no legally binding agreement has been entered into. There is no certainty that any transaction will materialize. Furthermore, critical conditions have yet to be met.
Reuters was the first to <a target="_blank" href="https://www.benzinga.com/quote/SWTX" rel="noreferrer noopener">report the potential deal</a>.
SpringWorks Therapeutics&#8217; first commercial product, Ogsiveo (nirogacestat), is a twice-daily oral medication that&nbsp;is the&nbsp;first and only&nbsp;FDA-approved&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/11/35974211/fda-approves-springworks-therapeutics-lead-therapy-as-first-for-subtype-of-soft-tissue-sarcomas" rel="noreferrer noopener">treatment for desmoid tumors.</a>
In January, rare diseases and cancer-focused SpringWorks Therapeutics reported preliminary fourth quarter and full-year 2024 U.S. net product revenue for Ogsiveo of $61.5 million and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42940198/springworks-therapeutics-reports-preliminary-fourth-quarter-and-full-year-2024-financial-results-a" rel="noreferrer noopener">$172.0 million, respectively</a>.
The company is scheduled to report Q4 earnings <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43331898/springworks-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-thursday" rel="noreferrer noopener">on 20 February</a>.
The company&#8217;s second potential commercial product, mirdametinib (NF1-PN), for adults and children with NF1-associated plexiform neurofibromas or NF1-PN, is under FDA review with <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42940198/springworks-therapeutics-reports-preliminary-fourth-quarter-and-full-year-2024-financial-results-a" rel="noreferrer noopener">PDUFA of 28 February</a>.
As of 31 December 2024, total preliminary cash, cash equivalents, and marketable securities were $461.9 million. SpringWorks expects its cash position to fund operations through profitability, which the company anticipates achieving in the first half of 2026.
Citing JPMorgan analysts Reuters report added that Merck KGaA&#8217;s oncology business, making up about 25% of its healthcare sales in 2024, could benefit from acquiring SpringWorks.
The report mentions the deal would complement Merck&#8217;s existing portfolio and create growth opportunities. Additionally, SpringWorks&#8217; products have the potential to help counter revenue losses from expiring drug patents and increased competition.
Price Action: SWTX stock is down 3.91% at $51.89 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/buybacks/25/02/43624237/sp-globals-ratings-power-q4-surge-capital-returns-sweeten-the-deal" target="_blank" rel="noreferrer noopener">S&amp;P Global&#8217;s Ratings Power Q4 Surge, Capital Returns Sweeten The Deal</a></li>
</ul>

Biotech

Large Cap

News

Health Care

Movers

General

MKGAF

MKKGY

SWTX

Germany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics

Benchmark analyst Mark Zgutowicz maintains DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) with a Buy and raises the price target from $180 to $220.

Price Target

Analyst Ratings

DASH

Benchmark Maintains Buy on DoorDash, Raises Price Target to $220

<a href="https://www.youtube.com/watch?v=aavRKJYuJkE" title="https://www.youtube.com/watch?v=aavRKJYuJkE">https://www.youtube.com/watch?v=aavRKJYuJkE</a>

Macro Economic Events

Economics

Federal Reserve

Fed Chair Powell Says Manufacturing Is Smaller Part Of Economy Than Before, Though Still Important; Healthy Manufacturing Is Important To Overall Economy

Morgan Stanley analyst Nigel Dally maintains Globe Life (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GL#NYSE">GL</a>) with a Equal-Weight and raises the price target from $123 to $125.

Morgan Stanley Maintains Equal-Weight on Globe Life, Raises Price Target to $125

Fed Chair Powell Says We Want To Run A Strong Labor Market, One Of The Benefits Is That Black-white Employment Gap Comes Down

Benchmark analyst Mike Hickey maintains Gambling.com Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAMB#NASDAQ">GAMB</a>) with a Buy and raises the price target from $16 to $18.

GAMB

Benchmark Maintains Buy on Gambling.com Gr, Raises Price Target to $18

Morgan Stanley analyst Vincent Andrews maintains Bunge Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>) with a Equal-Weight and lowers the price target from $90 to $74.

Morgan Stanley Maintains Equal-Weight on Bunge Global, Lowers Price Target to $74

Fed Chair Powell Says Fed Pursuing Mandate Is Single Best Thing Fed Can Do To Narrow Gaps By Race; Still Have Quite A Bit Of Equity Data On Our Website

GM CEO: We Think We Can Mitigate 30% To 50% Of Tariffs Without Deploying Capital

INTC

Intel shares are trading higher after reviewers praised its latest processor, the Core Ultra 9 275HX, as the "fastest chip yet".

<a href="http://www.forbes.com/sites/johnkang/2025/02/11/meta-in-talks-to-buy-korean-ai-chip-startup-founded-by-samsung-engineer/" title="http://www.forbes.com/sites/johnkang/2025/02/11/meta-in-talks-to-buy-korean-ai-chip-startup-founded-by-samsung-engineer/">http://www.forbes.com/sites/johnkang/2025/02/11/meta-in-talks-to-buy-korean-ai-chip-startup-founded-by-samsung-engineer/</a>

Meta Is In Talks To Acquire South Korean AI Chip Startup Furiosaai

Guidance

CORRECTION: FIS Expects Q1 2025 Revenue Of $2.485B - $2.510B Vs. $2.57B Estimate, Adjusted EPS Of $1.17-$1.22 Vs. $1.28 Estimate

JMP Securities analyst Mitch Germain maintains Safehold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAFE#NYSE">SAFE</a>) with a Market Outperform and lowers the price target from $35 to $32.

SAFE

JMP Securities Maintains Market Outperform on Safehold, Lowers Price Target to $32

Fed Chair Powell Says Don't Believe Musk Or Team Has Tried To Access Fed Systems; Commit To Letting Committee Know If So

Editor&#8217;s note: This story has been updated with additional details. 
Federal Reserve Chair Jerome Powell reiterated on Tuesday that policymakers are in no "hurry" to adjust interest rates, citing lingering inflation pressures despite significant progress toward the<a href="https://www.benzinga.com/news/econ-s"> Fed's 2% inflation goal.</a>
Speaking before the Senate Banking Committee in Washington, Powell described the economic landscape as one where "the economy is strong overall." with a labor market that has cooled from its overheated state but remains resilient.
Over the past four months, payroll job gains averaged 189,000 per month, while the unemployment rate held steady at 4% in January. Powell indicated that "the labor market is not a source of significant inflationary pressures."
On inflation, Powell highlighted a notable decline over the past two years but stressed that "inflation remains somewhat elevated."
The latest Personal Consumption Expenditures price index showed a 2.6% year-over-year increase as of December, with core PCE rising 2.8%, excluding volatile food and energy costs. 
<h3 class="wp-block-heading">Powell Stresses Caution In Interest Rate Policy</h3>
Since September, the Federal Open Market Committee has lowered the policy rate by a full percentage point from its peak. 
Powell described this shift as "appropriate in light of the progress on inflation and the cooling in the labor market."
Despite these moves, Powell reiterated that "we do not need to be in a hurry to adjust our policy stance." 
He stated that reducing interest rates &#8220;too fast or too much&#8221; could derail progress on inflation, while moving too slowly or too little "could unduly weaken economic activity and employment."
Going forward, the Fed will continue to remain data dependent, before making further policy adjustments.
<h3 class="wp-block-heading">Powell Pushes Back Recession Concerns, Refrains From Tariff Judgement</h3>
During the Q&amp;A session, Powell pushed back against recession risks and reiterated the broader strength of the economy. 
Sen. John Kennedy (R-LA) questioned the Fed's influence over long-term bond yields, to which Powell responded, "We have some influence, but mostly not." 
The Fed Chair indicated that long-term rates are driven by future short-term rate expectations, inflation risks, and the budget deficit—factors beyond the Fed's direct control. 
When asked if a president could remove a Federal Reserve Board member, Powell said, "It's not allowed under the law."
Sen. Bill Hagerty (R-TN) asked Powell if the neutral rate — the point where interest rates neither boost nor slow the economy — has risen.
&#8220;The neutral rate will have risen meaningfully," Powell said.
The chairman highlighted that concerns over labor market weakness and inflation have faded. Powell said that many of his colleagues also believe the neutral rate has moved higher, a shift from its historically low pre-pandemic levels.
On trade policy, Sen. Jack Reed (D-RI) referenced Powell's 2018 statement that "countries that have remained open to trade, that have not erected barriers, including tariffs, have grown faster and achieved higher incomes." 
Powell stood by that view but refrained from commenting on specific trade policies, including President Donald Trump's tariffs on China, Canada, and Mexico. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43627524/economists-betting-markets-predict-benign-january-inflation-what-could-go-wrong-this-time">Economists, Betting Markets Predict Benign January Inflation: What Could Go Wrong This Time?</a></li>
</ul>

Econ #s

Fed's Powell Reiterates No 'Hurry' To Cut Interest Rates As Inflation Remains 'Somewhat Elevated' (UPDATED)

Fed Chair Powell Says Seeing Insurance Pulling Out Of Parts Of Country, Would Have Significant Economic Consequences But Not Necessarily A Financial Stability Concern; Powell: Concern On Labor Market Has Diminished Considerably Since Mid-last Year

Morgan Stanley analyst Vincent Andrews maintains Archer-Daniels Midland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) with a Equal-Weight and lowers the price target from $52 to $47.

Morgan Stanley Maintains Equal-Weight on Archer-Daniels Midland, Lowers Price Target to $47

Morgan Stanley analyst Michael Cyprys maintains Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) with a Equal-Weight and raises the price target from $169 to $170.

Morgan Stanley Maintains Equal-Weight on Apollo Global Management, Raises Price Target to $170

Investors with a lot of money to spend have taken a bearish stance on Intuitive Machines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with LUNR, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 18 options trades for Intuitive Machines.
This isn't normal.
The overall sentiment of these big-money traders is split between 44% bullish and 50%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $31,620, and 17, calls, for a total amount of $864,107.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $10.0 to $25.0 for Intuitive Machines over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Intuitive Machines options trades today is 2439.8 with a total volume of 18,107.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Intuitive Machines's big money trades within a strike price range of $10.0 to $25.0 over the last 30 days.
<h3>Intuitive Machines Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739291431_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LUNR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$11.6</td>
<td>$10.85</td>
<td>$11.6</td>
<td>$10.00</td>
<td>$140.3K</td>
<td>7.9K</td>
<td>121</td>
</tr>
<tr>
<td>LUNR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$12.55</td>
<td>$11.55</td>
<td>$11.6</td>
<td>$10.00</td>
<td>$116.0K</td>
<td>7.9K</td>
<td>300</td>
</tr>
<tr>
<td>LUNR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/14/25</td>
<td>$0.99</td>
<td>$0.96</td>
<td>$0.98</td>
<td>$20.00</td>
<td>$78.6K</td>
<td>2.2K</td>
<td>1.2K</td>
</tr>
<tr>
<td>LUNR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$1.2</td>
<td>$1.13</td>
<td>$1.13</td>
<td>$21.00</td>
<td>$54.5K</td>
<td>856</td>
<td>517</td>
</tr>
<tr>
<td>LUNR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/14/25</td>
<td>$0.7</td>
<td>$0.56</td>
<td>$0.7</td>
<td>$20.00</td>
<td>$43.3K</td>
<td>2.2K</td>
<td>2.6K</td>
</tr>
</tbody>
</table>

<h3>About Intuitive Machines</h3>
Intuitive Machines Inc is a space exploration, infrastructure, and services company. It is a diversified space company focused on space exploration. It supplies space products and services to support sustained robotic and human exploration to the Moon, Mars, and beyond. Its products and services are offered through its four business units: Lunar Access Services, Orbital Services, Lunar Data Services, and Space Products and Infrastructure.
In light of the recent options history for Intuitive Machines, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Intuitive Machines Standing Right Now?</h3>
<ul>
<li>With a volume of 4,109,237, the price of LUNR is down -4.07% at $19.12. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 37 days.</li>
</ul>
<h3>Expert Opinions on Intuitive Machines</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $16.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from B of A Securities has revised its rating downward to Underperform, adjusting the price target to $16. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Intuitive Machines options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

LUNR

Decoding Intuitive Machines's Options Activity: What's the Big Picture?

Barclays analyst Peter Lawson maintained a Buy rating on Arcellx Inc (ACLX – Research Report) today and set a price target of $115.00. The company'...

Barclays Sticks to Their Buy Rating for Arcellx Inc (ACLX)

Canaccord Genuity analyst John Newman maintained a Buy rating on Arcellx Inc (ACLX – Research Report) today and set a price target of $121.00. John...

Positive Outlook for Arcellx Inc. Based on Promising Clinical Trial Results and Superior Safety Profile

William Blair analyst Sami Corwin has maintained their bullish stance on ACLX stock, giving a Buy rating today. Sami Corwin has given his Buy ratin...

Promising Prospects for Anito-cel in Relapsed Multiple Myeloma: Buy Rating Affirmed

UBS analyst Ashwani Verma raised the firm's price target on Arcellx (ACLX) to $114 from $106 and keeps a Buy rating on the shares. UBS believes Arc...

Arcellx price target raised to $114 from $106 at UBS

In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Buy rating on Arcellx Inc (ACLX – Research Report), with a price tar...

Promising Outlook for Arcellx Inc: Anito-cel Therapy Positioned as a Safer Alternative with Strong Market Potential

In a report released today, Richard Newitter from Truist Financial maintained a Buy rating on Arcellx Inc (ACLX – Research Report). The company's s...

Arcellx Inc (ACLX) Gets a Buy from Truist Financial

Oppenheimer laid out five "aspirational" potential takeover targets in biotech heading into the annual JPMorgan Health Care Conference. "We need mo...

Opco lists five potential biotech targets into JPMorgan conference

Viking Therapeutics among potential buyout candidates: Oppenheimer

Arcellx, Inc.: Trying To Build A Better Myeloma Cell Therapy

Baron Health Care Fund Q4 2024 Shareholder Letter

ACLX

AMGN

ARGNF

ARGX

AZNCF

BCAP

BPMC

BROE

EWTX

GILD

GKOS

ISRG

JANX

LEGN

NTRA

NUVL

RDNT

REGN

VKTX

VRTX

Press Releases

Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Arcellx to Participate in Two Upcoming Investor Conferences

Arcellx Provides First Quarter 2024 Financial Results

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

Arcellx Provides Second Quarter 2024 Financial Results and Business Updates

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition

Comments

Arcellx

Interés en corto

Arcellx (NASDAQ:ACLX) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL